

## RESEARCH ARTICLE

# Pdgfra-Cre mediated knockout of the aryl hydrocarbon receptor protects mice from high-fat diet induced obesity and hepatic steatosis

Francoise A. Gourronc<sup>1</sup>, Kathleen R. Markan<sup>2</sup>, Katarina Kulhankova<sup>3</sup>, Zhiyong Zhu<sup>4</sup>, Ryan Sheehy<sup>5</sup>, Dawn E. Quelle<sup>6</sup>, Leonid V. Zingman<sup>7</sup>, Zoya B. Kurago<sup>8</sup>, James A. Ankrum<sup>9</sup>, Aloysius J. Klingelutz<sup>10\*</sup>

**1** Department of Microbiology and Immunology, University of Iowa, Iowa City, IA, United States of America, **2** Department of Neuroscience and Pharmacology, Fraternal Order of Eagles Diabetes Research Center, University of Iowa, Iowa City, IA, United States of America, **3** Department of Pediatrics, University of Iowa, Iowa City, IA, United States of America, **4** Department of Internal Medicine, University of Iowa, Iowa City, IA, United States of America, **5** Department of Pharmacology, Kansas City University, Kansas City, KS, United States of America, **6** Department of Neuroscience and Pharmacology, Fraternal Order of Eagles Diabetes Research Center, University of Iowa, Iowa City, IA, United States of America, **7** Department of Internal Medicine, Fraternal Order of Eagles Diabetes Research Center, University of Iowa, Iowa City, IA, United States of America, **8** Department of Oral Biology and Diagnostic Sciences, Department of Pathology, Augusta University, Augusta, GA, United States of America, **9** Roy J. Carver Department of Biomedical Engineering, Fraternal Order of Eagles Diabetes Research Center, University of Iowa, Iowa City, IA, United States of America, **10** Department of Microbiology and Immunology, Fraternal Order of Eagles Diabetes Research Center, University of Iowa, Iowa City, IA, United States of America

\* [al-klingelutz@uiowa.edu](mailto:al-klingelutz@uiowa.edu)



## OPEN ACCESS

**Citation:** Gourronc FA, Markan KR, Kulhankova K, Zhu Z, Sheehy R, Quelle DE, et al. (2020) Pdgfra-Cre mediated knockout of the aryl hydrocarbon receptor protects mice from high-fat diet induced obesity and hepatic steatosis. PLoS ONE 15(7): e0236741. <https://doi.org/10.1371/journal.pone.0236741>

**Editor:** Qinghua Sun, The Ohio State University, UNITED STATES

**Received:** April 7, 2020

**Accepted:** July 13, 2020

**Published:** July 30, 2020

**Copyright:** © 2020 Gourronc et al. This is an open access article distributed under the terms of the [Creative Commons Attribution License](https://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

**Data Availability Statement:** All relevant data are within the paper and its Supporting Information files.

**Funding:** This work was supported by a University of Iowa Fraternal Order of Eagles Diabetes Research Center Pilot Award as well as a Mark Stinski Department of Microbiology Developmental Award to AJK and an NIH K01DK111758 awarded to KRM. The funders had no role in study design,

## Abstract

Aryl hydrocarbon receptor (AHR) agonists such as dioxin have been associated with obesity and the development of diabetes. Whole-body Ahr knockout mice on high-fat diet (HFD) have been shown to resist obesity and hepatic steatosis. Tissue-specific knockout of Ahr in mature adipocytes via adiponectin-Cre exacerbates obesity while knockout in liver increases steatosis without having significant effects on obesity. Our previous studies demonstrated that treatment of subcutaneous preadipocytes with exogenous or endogenous AHR agonists disrupts maturation into functional adipocytes *in vitro*. Here, we used platelet-derived growth factor receptor alpha (Pdgfra)-Cre mice, a Cre model previously established to knock out genes in preadipocyte lineages and other cell types, but not liver cells, to further define AHR's role in obesity. We demonstrate that Pdgfra-Cre Ahr-floxed (Ahr<sup>fl/fl</sup>) knockout mice are protected from HFD-induced obesity compared to non-knockout Ahr<sup>fl/fl</sup> mice (control mice). The Pdgfra-Cre Ahr<sup>fl/fl</sup> knockout mice were also protected from increased adiposity, enlargement of adipocyte size, and liver steatosis while on the HFD compared to control mice. On a regular control diet, knockout and non-knockout mice showed no differences in weight gain, indicating the protective phenotype arises only when animals are challenged by a HFD. At the cellular level, cultured cells from brown adipose tissue (BAT) of Pdgfra-Cre Ahr<sup>fl/fl</sup> mice were more responsive than cells from controls to transcriptional activation of the thermogenic uncoupling protein 1 (Ucp1) gene by norepinephrine, suggesting an ability to burn more energy under certain conditions. Collectively, our results show that knockout of

data collection and analysis, decision to publish, or preparation of the manuscript.

**Competing interests:** The authors have declared that no competing interests exist.

**Abbreviations:** AHR/Ahr, Aryl hydrocarbon receptor protein/gene; BAT, Brown adipose tissue; eWAT, Epididymal white adipose tissue (i.e. visceral white fat); fl/fl, *Flox/flox*; GTT, Glucose tolerance test; HFD, High fat diet; ITT, Insulin tolerance test; iWAT, Inguinal white adipose tissue (i.e. subcutaneous white fat); NE, Norepinephrine; PCB, Polychlorinated biphenyl; *Pdgfra*, Platelet-derived growth factor receptor alpha; Q-RT-PCR, Quantitative reverse transcriptase polymerase chain reaction; TCDD, 2,3,7,8-Tetrachlorodibenzodioxin; UCP1/Ucp1, Uncoupling protein 1 protein/gene; WAT, White adipose tissue.

Ahr mediated by *Pdgfra*-Cre is protective against diet-induced obesity and suggest a mechanism by which enhanced UCP1 activity within BAT might confer these effects.

## Introduction

Metabolic syndrome, a cluster of conditions (i.e. increased blood pressure, high blood sugar, central adiposity, elevated cholesterol or triglyceride levels) that increase the risk of heart disease, stroke, and type II diabetes [1], has increased dramatically in the past several decades in the U.S. and worldwide leading to enormous health-related costs [2, 3]. Adipose tissue is critical for normal metabolism and its dysfunction plays an essential role in the development of metabolic syndrome [4–6]. Adipose tissue is necessary for regulation of inflammation as well as secretion of adipokines such as adiponectin and leptin [7]. Adipose tissue is much more diverse than previously appreciated and brown, white, and beige adipose tissues play distinct roles in energy homeostasis. White adipose tissue (WAT) is found in different anatomical depots (e.g. subcutaneous and visceral) each with different attributes while BAT is found predominantly intrascapular in rodents and primarily within deep regions of the neck in humans [7–9]. Over-accumulation of triglycerides in mature white and brown adipocytes causes them to become hypertrophic, inflammatory, and pathological.

More than 10% of adipocytes in the human body are replaced annually through adipogenesis of precursor stem cells [10]. Adipogenesis provides flexibility to meet metabolic needs but also a vulnerability as endogenous and environmental factors (effectors or repressors) can disrupt normal adipogenesis [11]. Disruption of adipogenesis can result in stress on mature adipocytes leading to dysfunctional adipose tissue and disease [4, 10]. This dysfunction in adipogenesis and adipose tissue results in loss of insulin sensitivity in adipocytes, an increase in cytokine production, and loss of adipokine signaling [7]. Loss of insulin sensitivity and inhibition of the thermogenic response in adipose tissue are key initiating events in the development of metabolic syndrome [12].

The aryl hydrocarbon receptor (AHR), was first identified as the mediator of the toxin TCDD (2,3,7,8-Tetrachlorodibenzodioxin; also referred to as dioxin) [13]. AHR contains a promiscuous ligand-binding pocket that can bind to many types of endogenous and exogenous compounds [14]. Upon activation, AHR goes to the nucleus and binds a co-activator called ARNT (aryl hydrocarbon receptor nuclear translocator) to activate or repress numerous genes [15, 16]. AHR is expressed ubiquitously in fetal and adult tissues including adipose tissue [15].

AHR has been implicated in several physiologic and pathologic conditions including the development of metabolic syndrome [17–21]. Studies have linked dioxin exposure to an increased risk for diabetes [22] and other studies associate exposure to dioxin-like PCBs (polychlorinated biphenyls) with the development of insulin resistance and diabetes [23–27]. The mechanisms by which AHR ligands cause or exacerbate metabolic syndrome are unclear. Certain AHR agonists including dioxin have been shown to inhibit the proper maturation of precursor cells into adipocytes [28–32]. In published studies, we showed that PCB126 causes a proinflammatory response in preadipocytes and inhibits adipogenesis [33, 34]. In addition to man-made AHR ligands, several endogenous and microbiome-derived metabolites can act as AHR agonists [35]. These include kynurenine, FICZ, indole, and indoxyl sulfate (IS), all tryptophan metabolites.

Whole body Ahr knockout mice are known to exhibit developmental defects and have decreased fertility [36, 37]. Systemic Ahr deficiency in mice and rats has been shown to protect

against high fat diet (HFD) induced obesity, hepatic steatosis, insulin resistance and inflammation [38–40]. Chemical inhibition of AHR has also protects against obesity caused by HFD [38, 41]. Conversely, mice with an *Ahr* allele that confers more sensitivity to AHR ligands were found to be more susceptible to HFD induced obesity [42]. What cells and tissues are directly involved in these AHR-mediated effects remains unclear.

Tissue specific models of *Ahr* loss have yielded differing results compared to whole body knockouts or chemical inhibition studies. For example, a recent study in which *Ahr* was ablated in a tissue-specific manner through expression of Cre from an adiponectin promoter (i.e. in mature adipocytes) caused an increase in obesity on HFD at baseline [43]. Our *in vitro* studies would suggest that preadipocytes, not adipocytes, are more susceptible to effects mediated by activated AHR [33]. Interestingly, liver-specific knockout of *Ahr* in mice had no effect on weight or adiposity in response to HFD but did lead to increased liver steatosis [39].

Clearly, questions remain as to how AHR mediates effects on obesity and steatosis when mice are on a HFD. To address this issue, we generated mice in which *Ahr* was selectively knocked out in cells that expressed *Pdgfr $\alpha$* -Cre. This model has been used to inactivate genes in preadipocyte lineages, before they become adipocytes [44–50]. While this Cre model can also lead to *Ahr* knockout in certain tissues other than preadipocytes and adipocytes, it does not result in knockout in the liver [46], thus allowing an assessment of effects that are not directly related to the AHR's well-known role in the liver [37, 51, 52]. We found that *Pdgfr $\alpha$* -Cre mediated knockout of *Ahr* protected mice from HFD induced obesity and liver steatosis. Our results indicate that AHR activity in cell lineages that express *Pdgfr $\alpha$* , which includes preadipocytes and adipocytes, is important for mediating the effects of HFD in mice.

## Materials and methods

### Animals

*Ahr*<sup>flox/flox</sup> (*Ahr*<sup>fl/fl</sup>) C57/BL6 mice (Jackson Labs 006203) have been described previously [37]. The *Pdgfr $\alpha$* -Cre mouse line (Jackson Labs 013148) has been used previously in preadipocyte lineage tracing studies and in studies to knockout genes in preadipocytes [44–50]. It should be noted that the *Pdgfr $\alpha$* -Cre is highly active in, but not limited to, preadipocytes of adipose lineages [46]. A lineage tracing study demonstrated less than 5% recombination of cells in liver tissue [44]. Both strains of mice were purchased from Jackson Laboratories. The *Ahr*<sup>fl/fl</sup> were obtained as a homozygous breeding pair. To achieve tissue-specific knockout of *Ahr*, *Pdgfr $\alpha$* -Cre<sup>pos/neg</sup> (Cre always maintained in heterozygous state and only in males) mice were bred to homozygosity for floxed *Ahr* (*Ahr*<sup>fl/fl</sup>). For generation of *Pdgfr $\alpha$* -Cre<sup>pos</sup> *Ahr* knockout mice and controls, male *Pdgfr $\alpha$* -Cre<sup>pos/neg</sup> (heterozygous Cre)/*Ahr*<sup>fl/fl</sup> were bred to female *Ahr*<sup>fl/fl</sup> mice that did not express Cre. The offspring showed a 50:50 ratio of Cre<sup>pos</sup> and Cre<sup>neg</sup> genotypes as assessed by PCR for Cre. Male mice were used in this study because male C57/BL6 mice exhibit significant and consistent development of obesity and insulin resistance when on HFD [53].

To verify *Ahr* recombination in adipose tissue, BAT, subcutaneous and visceral WAT, muscle, heart, liver, kidney and spleen tissues were removed from *Pdgfr $\alpha$* -Cre<sup>pos</sup> adult mice and processed for DNA isolation after homogenization. Verification of recombination in different tissues or lack thereof was performed using published primers and conditions [37]. An explanation of expected patterns of recombination (excised) or non-recombination (unexcised) of the PCR products is shown in S1A Fig.

Mice on HFD were fed 60% high fat diet (HFD; Research Diets, D12492i) for the indicated time. Control diet (Research Diets, D12550j) with 10% fat and a matched calorie content (provided by complex carbohydrates) was used for comparison. Mice were placed on their specific

diets starting at 6–7 weeks of age. Different genotypes were dispersed randomly in cages. The number of mice used in each experiment is indicated in the figure legends. Mouse weights were measured weekly.

This study was carried out in strict accordance with the recommendations in the Guide for the Care and Use of Laboratory Animals of the National Institutes of Health. The protocol was approved by the University of Iowa IACUC (Protocol number 8091538). Tail snips were only taken at the time of weaning at 3 weeks of age. Mice were monitored daily by the Animal Care Facility staff for signs of distress and/or fighting. Fighting animals were separated. All efforts were used to minimize suffering during procedures. Adult animals were euthanized using CO<sub>2</sub> followed by cervical dislocation to ensure death. Neonates were euthanized by rapid decapitation with a scissors.

### Glucose and insulin tolerance tests

Following a 6-hour fast, time 0 blood was collected via tail bleed followed by an intraperitoneal (i.p.) injection of glucose (2 g/kg for control diet and 1.3 g/kg for HFD). Different amounts of glucose were used for the control-fed and HFD groups because HFD-fed animals have a lower percent lean body mass as compared to total body weight thus potentially biasing results towards showing impaired glucose tolerance in the high-fat group [54–56]. Regardless, statistical comparisons were only made between mice that received the same amount of glucose per body weight. Tail blood was then collected into 300K2E microvette EDTA tubes (Sarstedt) over the course of 120 min and then centrifuged at 3000 rpm for 30 min at 4°C for the separation of plasma. Plasma glucose was then measured using the Autokit Glucose Reagent (WAKO) per manufacturer's instructions. For insulin tolerance tests (ITTs), mice were fasted 6 h. Time 0 blood was obtained via tail bleed followed by an intraperitoneal (i.p.) injection of insulin (at 0.75 units/kg). Tail blood was collected and plasma glucose analyzed as described above.

### Fat and liver tissue histology

After euthanizing, mice were dissected to remove liver and fat depots (subcutaneous, visceral, and brown). Tissues were fixed in 10% phosphate-buffered formalin and then processed, sectioned and stained by hematoxylin and eosin (H&E) using standard pathology methods at the University of Iowa Comparative Pathology Core. Coded liver sections were evaluated and scored by a pathologist blinded to the experimental conditions. Each of the sections was analyzed by photographing 10 non-overlapping high-power fields (400x) centered on the portal vein for consistency, and the percentage of lipid-containing hepatocytes was recorded, followed by statistical analysis of the scores (GraphPad Prism). Adipocyte number and size in inguinal WAT (iWAT) or epididymal WAT (eWAT), also referred to as subcutaneous and visceral WAT, respectively, were quantified using Adiposoft software (ImageJ) [57]. Because of small size and cellular complexity, BAT was not amendable to this type of analysis.

### Adiposity measurement

Body composition was measured using a rodent-sized NMR machine (Bruker Minispec LF50) at the Fraternal Order of Eagles Diabetes Research Center (FOEDRC) Metabolic Core. The percent lean or fat mass is calculated by dividing the lean or fat mass by the total weight and multiplying by 100. The addition of the percent lean and percent fat does not add up to one hundred percent because of additional mass from fluid and bone density not accounted for via NMR.

## Isolation and culturing of BAT from pups, NE-treatment, and Q-RT-PCR

Neonate mice were euthanized and dissected to isolate BAT. BAT from individual pups was dissociated using collagenase and cultured in one well of a 12-well plate according to published protocols [56]. Confluent wells were passaged 1:4 into 4 new wells. One well was used for isolation of DNA for genotyping for assessing the status of Cre and Ahr excision status (see above) whereas the other wells were used for norepinephrine (NE) treatments to induce a thermogenic response. Cells were treated with 10  $\mu$ M NE or vehicle for 6 hours followed by RNA isolation. RNA was isolated using Trizol followed by column purification (RNA Easy, Qiagen) with DNase treatment. RNA was reverse transcribed according to published protocols [58]. Quantitative PCR was performed using primers for 18S (internal control) or Ucp1. Sequences of primers were Ucp1 forward, CAA GAG GAA GGG ACG CTC AC; Ucp1 reverse AGT TGT CGG GTT CAC CAT CC; Adiponectin forward GCA GAG ATG GCA CTC CTG GA; Adiponectin reverse CCC TTC AGC TCC TGT CAT TCC; 18S forward AGG GGA GAG CGG GTA AGA GA; 18S reverse GGA CAG GAC TAG GCG GAA CA.

## Statistical analysis


Statistical analysis was performed using GraphPad Prism software. Numbers of replicates/animals and the various tests that were performed are noted in the figure legends.

## Results

### ***Pdgfr $\alpha$* -Cre Ahr knockout mice are resistant to high-fat diet induced obesity and increased fat mass**

We used a previously described *Pdgfr $\alpha$* -Cre system that has been shown in lineage tracing studies to be active in preadipocyte lineages in order to test the function of the AHR in preadipocytes [44, 46]. This model has been used in different studies to knockout genes in preadipocytes and subsequently in the adipocytes that are derived from them [47–50]. For Ahr knockout, we bred *Pdgfr $\alpha$* -Cre with *Ahr<sup>fl/fl</sup>* on a pure C57/BL6 background. Mature *Pdgfr $\alpha$* -Cre<sup>pos/neg</sup>/*Ahr<sup>fl/fl</sup>* mice were then assessed for recombination in fat depots and other tissues by isolation of tissue and assessment of recombination by PCR as previously described [37]. High levels of recombination were detected in all fat depots, indicating that *Pdgfr $\alpha$* -Cre caused excision of the Ahr floxed gene (S1A and S1B Fig). In contrast, minimal levels of recombination were observed in liver, as reported previously in a lineage tracing study [44]. Other tissues, including heart, spleen, and to some extent, kidney and muscle also exhibited recombination, indicating a low level of Ahr excision in these tissues, likely due to PDGFR $\alpha$  being expressed in certain cellular components (e.g. endothelial cells) of these tissues [59]. To verify clean knockout in preadipocytes, stromal vascular fractions were isolated and cultured from the BAT of pups that were either *Pdgfr $\alpha$* -Cre<sup>pos</sup> or Cre<sup>neg</sup>. The vast majority of the cells that grow from SVF are preadipocytes and, accordingly, PCR results indicated clear excision of Ahr in *Pdgfr $\alpha$* -Cre<sup>pos</sup> cells but not in Cre<sup>neg</sup> cells (S1C Fig). Thus, as previously reported, the *Pdgfr $\alpha$* -Cre is highly active in, but not limited to, preadipocytes of adipose lineages [46]. The low level of excision in the liver makes it a useful model for separating out those phenotypic changes following deletion of the AHR that are not directly associated with liver. No noticeable differences in the number of pups with the different Cre genotypes were observed. In an assessment of 8 breeding pairs, there were 17 male *Pdgfr $\alpha$* -Cre<sup>pos</sup> offspring and 18 male Cre<sup>neg</sup> offspring or 48.6% and 51.4%, respectively, indicating that *Pdgfr $\alpha$* -Cre knockout of Ahr does not significantly affect male survival.





**Fig 1. Effects of HFD (60% fat) or lower-fat (10% fat) calorie-matched control diet on weights of mice without *Ahr* knockout ( $Cre^{neg}$ ) or with *Pdgfra*-*Cre* knockout ( $Pdgfra-Cre^{pos}$ ).** A. Weights of mice on control diet; B. Weights of mice on HFD. Mice were placed on HFD or control diet at 6 to 7 weeks of age and weighed weekly as described in the Materials and Methods.  $Cre^{neg}$  and  $Pdgfra-Cre^{pos}$  groups consisted of 7 mice each for HFD and 6 mice each for control diet. Statistics were performed using 2-way ANOVA with multiple comparisons in GraphPad Prism. \* <math><0.05</math>, \*\* <math><0.01</math>, \*\*\* <math><0.001</math>. Error bars represent standard error of the mean.


<https://doi.org/10.1371/journal.pone.0236741.g001>

After weaning at 3 weeks, mice were kept on regular chow until 6–7 weeks of age during which time genotyping was performed for *Cre* expression.  $Pdgfra-Cre^{pos/neg}/Ahr^{fl/fl}$  knockout mice (referred to here and in figures as  $Pdgfra-Cre^{pos}$ ) at 6–7 weeks of age were found to be more variable and, on average, statistically weighed less than  $Cre^{neg}/Ahr^{fl/fl}$  wildtype controls (referred to here and in figures as  $Cre^{neg}$ ) (S2 Fig). The mice were randomly separated into HFD (60% fat) and calorie-matched control diet (10% fat) cages. While body weights of the  $Cre^{neg}$  and  $Pdgfra-Cre^{pos}$  genotypes converged by week 3 on the control diet and remained similar for the rest of the experiment (Fig 1A), body weight between genotypes began to diverge at week 5 of HFD at which point the  $Cre^{neg}$  mice trended toward heavier weights, becoming significantly different by week 8 (Fig 1B). By the end of the observation period at 14 weeks,  $Cre^{neg}$  mice were, on average, more than 10 grams heavier than  $Pdgfra-Cre^{pos}$  animals lacking *Ahr* in preadipocytes (Fig 1B). Of note, there was no significant difference in food intake between the genotypes on either HFD or control diet (S3 Fig). These results indicate the difference in body weights between genotypes was driven mainly by the HFD.

To assess body composition, both cohorts of mice on control diet or HFD were subjected to whole-body NMR at week 14. No differences in adiposity were observed between  $Cre^{neg}$  and  $Pdgfra-Cre^{pos}$  genotypes on control diet (Fig 2A). In contrast,  $Pdgfra-Cre^{pos}$  mice on HFD had higher lean mass and lower percent fat overall than  $Cre^{neg}$  mice (Fig 2B), indicating that *Pdgfra*-*Cre* mediated knockout of *Ahr* protects against accumulation of fat.

### Glucose and insulin tolerance in *Pdgfra*-*Cre* *Ahr* knockout mice

Since obesity is associated with the development of type II diabetes, we performed glucose tolerance tests (GTT) and insulin tolerance tests (ITT) on the mice on HFD or control diet. As seen in Fig 3A and 3B, there were no differences between  $Cre^{neg}$  and  $Pdgfra-Cre^{pos}$  genotypes during a GTT or ITT while on the control diet. As expected for mice on long-term HFD, higher levels of basal glucose were observed in the HFD groups but, interestingly, there were also no differences between genotypes when on HFD in the ability to clear plasma glucose as



**Fig 2. Effects of HFD or control diet on adiposity of mice without *Ahr* knockout (*Cre*<sup>neg</sup>) or with *Pdgfra*-*Cre* knockout (*Pdgfra*-*Cre*<sup>pos</sup>).** A. Adiposity of mice on control diet; B. Adiposity of mice on HFD. Fat mass was assessed using NMR at 14 weeks on HFD or control in mice as described in the Materials and Methods. *Cre*<sup>neg</sup> and *Pdgfra*-*Cre*<sup>pos</sup> groups consisted of 7 mice each for HFD and 6 mice each for control diet. The percent lean or fat mass is calculated by dividing the lean or fat mass by the total weight and multiplying by 100. The addition of the percent lean and percent fat does not add up to one hundred percent because of additional mass from fluid and bone density. Statistics were performed using a 2-way ANOVA with multiple comparisons in GraphPad Prism. \* <math><0.05</math>, \*\* <math><0.01</math>. Error bars represent standard error of the mean.


<https://doi.org/10.1371/journal.pone.0236741.g002>

measured by GTT (Fig 3C). HFD *Pdgfra*-*Cre*<sup>pos</sup> *Ahr* mice, however, displayed significantly enhanced insulin sensitivity indicated by ITT results at the individual 60- and 90-minute time points compared to HFD *Cre*<sup>neg</sup> mice (Fig 3D). However, comparison of overall glucose levels at all time points using area under the curve (AUC) analysis between the *Cre*<sup>neg</sup> and *Pdgfra*-*Cre*<sup>pos</sup> genotypes on HFD did not demonstrate statistically significant differences in the ITT ( $p = 0.07$ ). Thus, although *Pdgfra*-*Cre* mediated knockout of *Ahr* appeared to offer some protection against HFD-induced insulin resistance at certain time points, the overall effect on insulin sensitivity was not considered significant.

### Decreased hepatic steatosis and smaller adipocyte size in *Pdgfra*-*Cre* *Ahr* knockout mice on HFD

Obesity is highly associated with liver steatosis (i.e. accumulation of lipid in hepatocytes) [60]. Therefore, livers obtained from mice on HFD were evaluated as described in the Materials and Methods. Examples of H&E sections *Cre*<sup>neg</sup> and *Pdgfra*-*Cre*<sup>pos</sup> mice are shown in Fig 4. As expected, *Cre*<sup>neg</sup> mice on HFD exhibited steatosis, demonstrated by numerous lipid vacuoles in the hepatocytes (Fig 4A, ranging from 15–20% in one of the samples, to over 75% in others (see S1 Table). Interestingly, *Pdgfra*-*Cre*<sup>pos</sup> *Ahr* knockout mice on HFD exhibited no steatosis, with less than 5% of hepatocytes containing lipid vacuoles in all samples examined (Fig 4B). The severity of steatosis was scored and ranked (S1 Table), demonstrating significant differences between *Cre*<sup>neg</sup> and *Pdgfra*-*Cre*<sup>pos</sup> mice on HFD ( $p < 0.05$ , Wilcoxon Rank-Sum). This result is of interest since *Pdgfra*-*Cre* does not knock out *Ahr* in liver, indicating that protection against steatosis in the liver is likely due to the genetic deletion of *Ahr* in other tissues such as adipose.

Microscopic examination of H&E stained sections of various fat depots demonstrated that *Pdgfra*-*Cre*<sup>pos</sup> *Ahr* knockout mice on HFD had much smaller adipocytes than those in *Cre*<sup>neg</sup> mice on HFD (Fig 5A). This was true of iWAT, eWAT, and BAT. Adiposoft software, a



**Fig 3. Effects of HFD or control diet on glucose and insulin tolerance in mice without AHR knockout (*Cre*<sup>neg</sup>) or with *Pdgfra*-*Cre* Ahr knockout (*Pdgfra*-*Cre*<sup>pos</sup>).** Glucose tolerance test (GTT) (A) and insulin tolerance test (ITT) (B) on mice on control diet. GTT (C) and ITT (D) on mice on HFD. GTT and ITT were performed at 14 weeks on indicated diets as described in the Materials and Methods. *Cre*<sup>neg</sup> and *Pdgfra*-*Cre*<sup>pos</sup> groups consisted of 7 mice each for HFD and 6 mice each for control diet. Error bars represent standard error of the mean. Asterisks above the curve represent statistical significance of comparisons of individual time points using 2-way ANOVA with multiple comparisons without corrections using Fishers LSD in GraphPad Prism. \* <math><0.05</math>, \*\* <math><0.01</math>. Analysis of AUC of overall glucose levels comparing different genotypes was also performed but no statistically significant differences were observed in any of the above comparison.


<https://doi.org/10.1371/journal.pone.0236741.g003>

program developed specifically for characterization of WAT [57] was used to quantify adipocyte size in WAT. This analysis indicated that the iWAT and eWAT of *Pdgfra*-*Cre*<sup>pos</sup> Ahr knockout mice had on average smaller adipocytes with the distribution of adipocyte size narrower compared to controls (Fig 5B). Thus, our results suggest that *Pdgfra*-*Cre* mediated knockout of Ahr protects against adipocyte hypertrophy in all fat depots of mice on HFD.

### BAT from *Pdgfra*-*Cre* Ahr knockout mice exhibits greater thermogenic potential following norepinephrine treatment

Previously, it was shown that whole-body Ahr knockout mice on HFD have increased transcript levels of the thermogenic uncoupling gene *Ucp1* in BAT as compared wild type mice, potentially explaining how Ahr knockout could protect against HFD induced obesity [38]. Thermogenic induction of *Ucp1* is mediated through cold exposure or by beta adrenergic







**Fig 4. Liver pathology in mice on HFD without Ahr knockout ( $Cre^{neg}$ ) or with Pdgfra-Cre knockout ( $Pdgfra-Cre^{pos}$ ).** Shown are representative examples from each genotype. A.  $Cre^{neg}$  on HFD, B.  $Pdgfra-Cre^{pos}$  on HFD. Images were taken using a Nikon Eclipse E800 microscope at 200X. Scale bars are 100 micrometers.

<https://doi.org/10.1371/journal.pone.0236741.g004>

receptor activators such as norepinephrine [61]. To characterize the effects of Pdgfra-Cre-mediated knockout of Ahr on BAT responses to thermogenic inducing agents, we isolated and cultured SVF from BAT of neonates, verified Ahr gene excision status (S1C Fig), differentiated the cells *in vitro*, and then stimulated the cultures with norepinephrine (NE). RNA was isolated to assess Ucp1 transcript levels by Q-RT-PCR. As shown in Fig 6A, the levels of NE-induced Ucp1 transcripts were significantly higher in Pdgfra-Cre<sup>pos</sup> Ahr knockout adipocytes than in  $Cre^{neg}$  adipocytes, indicating that knockout of Ahr leads to a more robust thermogenic response in BAT. Assessment of transcript levels of adiponectin, a marker of adipocyte differentiation, indicated no differences in ability of the cells from both genotypes to differentiate (Fig 6B). These results, combined with the smaller size of KO brown adipocytes and decreased brown adipocyte lipid accumulation, suggests increased level of energy expenditure in Pdgfra-Cre Ahr knockout mice, presenting a plausible mechanism by which Pdgfra-Cre mediated knockout protects against obesity and steatosis.

## Discussion

AHR continues to be a source of significant interest regarding its role in the development of metabolic syndrome, obesity, steatosis, cardiovascular disease, and diabetes. AHR responds to many different endogenous, bacterially-produced, and synthetic man-made compounds that include numerous persistent organic pollutants that people are exposed to on a regular basis [13, 14]. Further, there is compelling evidence that AHR activation causes inflammation in endothelium, the liver, and adipose tissue [32, 34, 62–64]. Depending on the context and the type of AHR ligand, AHR has been shown to inhibit adipogenesis or act as an obesogen. Our previous studies using human cells indicated that the AHR agonist, PCB126, acts through AHR on preadipocytes to inhibit adipogenesis [28–32] and blocks norepinephrine-mediate induction of UCP1 in adipocytes derived from PCB126-treated preadipocytes [65]. Interestingly, in the current study, we found that knock out of Ahr using Pdgfra-Cre, a model that has been shown in lineage tracing studies to act in preadipocytes, but not the liver, protected mice from HFD-induced obesity and steatosis. Adipocytes derived from preadipocytes of BAT from




**Fig 5. Adipose tissue pathology in mice on HFD without *Ahr* knockout ( $Cre^{neg}$ ) or with *Pdgfra*-Cre *Ahr* knockout ( $Pdgfra$ - $Cre^{pos}$ ).** A. Shown are representative examples of  $Cre^{neg}$  and  $Pdgfra$ - $Cre^{pos}$  mice on HFD for eWAT, iWAT, and BAT. Scale bars are 100 micrometers. B. Quantitation of adipocyte sizes in eWAT and iWAT fat depots of  $Cre^{neg}$  or  $Pdgfra$ - $Cre^{pos}$  mice on HFD. Quantitation was performed using the Adiposoft program in ImageJ. The upper panels represent the mean and the error bars are standard deviation. Unpaired T-test, \* $p < 0.05$ . The lower panels contain descriptive graphs to show the 25<sup>th</sup>, 50<sup>th</sup>, and 75<sup>th</sup> quartiles to illustrate the large differences in droplet sizes between the groups.

<https://doi.org/10.1371/journal.pone.0236741.g005>

*Pdgfra*-Cre *Ahr* knockout mice were more responsive to norepinephrine-mediated induction of the thermogenic uncoupling protein UCP1. Our results suggest that the effects of AHR on metabolic health are at least partly mediated through adipose tissue and that effects on UCP1 induction may play a role.

Other groups, using whole-body *Ahr* knockout, have also demonstrated a protective effect of AHR loss against HFD-induced obesity [38, 66, 67]. In those studies, protection against HFD-induced insulin resistance was also observed. While the results of our studies with the *Pdgfra*-Cre mediated knockout mice were suggestive of protection against insulin resistance, the effects were not overtly significant. This could be because *Ahr* knockout in other tissues besides those that express *Pdgfra* are important for protection against insulin resistance. Regardless, the collective results of these studies point to the possibility that HFD acts through AHR to cause obesity and steatosis, potentially through alteration in production of a metabolite (or metabolites) that acts as an AHR ligand. While the identity of this metabolite is unknown, there is evidence that HFD can alter levels of known AHR agonists such as tryptophan catabolites generated in the kynurenine pathway, for example [68]. Given that knockout of AHR (whole body or *Pdgfra*-Cre mediated) can protect against obesity, it is reasonable to propose that this metabolite is an AHR agonist. If it were, instead, an antagonist then it would follow that *Ahr* knockout would more likely increase obesity, which we did not observe. One possibility is that the metabolite or metabolites could act on preadipocytes and/or adipocytes to increase adipogenesis thereby increasing overall lipid accumulation in adipocytes to cause obesity. Another possibility, and one that is favored by our current data, is that an HFD-induced AHR agonist blocks preadipocytes from becoming thermogenically responsive



**Fig 6. Norepinephrine induced induction of *Ucp1* in BAT.** A. Ratios of norepinephrine-induced *Ucp1* in BAT from neonate pups of  $Cre^{neg}$  (no *Ahr* knockout) or  $Pdgfra$ - $Cre^{pos}$  *Ahr* knockout genotypes. Treatments and Q-RT-PCR were performed as described in the Materials and Methods comparing the ratio of *Ucp1* transcript in NE-treated versus baseline in 4  $Cre^{neg}$  and 6  $Pdgfra$ - $Cre^{pos}$  littermates. B. Transcript levels of the differentiation marker, adiponectin, in cells of mice of different genotypes. Q-RT-PCR was performed as described in the Materials and Methods. Statistics were performed using a Wilcoxon nonparametric test in GraphPad Prism. Error bars represent standard error of the mean. \*\* $p < 0.01$ .

<https://doi.org/10.1371/journal.pone.0236741.g006>

adipocytes, thus decreasing energy expenditure and contributing to obesity. Our data would suggest that this could be at the level Beta-adrenergic receptor and/or the level of Ucp1 transcription. Knockout of Ahr in BAT preadipocytes/adipocytes may prevent these AHR agonist-mediated effects. Similarly, HFD-induced AHR agonists may also prevent being in subcutaneous adipocyte lineages, inhibiting thermogenic responses in these fat depots, as well. In future studies, it will be of interest to assess whole body energy expenditure in the *Pdgfra*-Cre Ahr knockout mice compared to controls, particularly in the context of known AHR agonists, to determine if there are differences.

Interestingly, a role for AHR in regulation of energy expenditure through its interaction with circadian clock proteins has been explored previously [38, 67, 69, 70]. AHR forms a heterodimer with the circadian clock protein Bmal1 and functionally inhibits CLOCK/BMAL1 activity. Physiological activation of AHR through naturally occurring endogenous ligands may inhibit clock function. Whole-body knock out of Ahr was shown to be associated with higher levels of Ucp1 transcript levels as compared to controls in brown fat of mice on HFD [38]. This same study also reported that whole body Ahr knockout enhances behavioral responses to changes in light-dark cycle and increased the rhythmic amplitude of circadian clock genes as well as altered rhythms of glucose and insulin [67]. These studies demonstrate an already established role for the AHR in regulating energy metabolism, thermogenic responsiveness and glucose and insulin homeostasis.

Initially, our results along with studies published by others using whole body Ahr knockout appear in conflict with a report in which it was shown that knockout of Ahr in mature adipocytes through expression of adiponectin-Cre actually exacerbated HFD-induced obesity [33]. One way to explain this discrepancy is that knockout in preadipocytes or whole-body knockout would be expected to have more profound effects on how HFD affects the process of adipogenesis and the maturation of cells into functional thermogenically-responsive adipocytes. Delay of knockout of Ahr until the adipogenesis program is fully activated (when adiponectin is expressed) may result in a completely different phenotype with different responses to AHR ligands. These converse effects also suggest cell autonomous versus non-autonomous actions of the AHR at the level of adipose tissue. Thus, the timing of Ahr knockout during the course of adipogenesis may be important for determining the outcome.

We cannot rule out other cell types such as skeletal muscle and heart may play a role in mediating the effects of the AHR that we observed in our studies given that *Pdgfra*-Cre is active in other cell types. Muscle is highly relevant to energy expenditure. While others have reported that *Pdgfra*-Cre activity is low in muscle [44] and our results indicate minimal Ahr excision in muscle, it is still possible that Ahr knockout in certain muscle cells are playing a role in the phenotype that we observed. Clearly, further studies are warranted to identify the both the potential AHR metabolite and the target cell population(s).

Confounding the interpretation of the role of AHR in metabolic syndrome or any other diseases in future studies is the observation that not all AHR agonists act in the same fashion. Depending on the AHR agonists, different effects on obesity in animals have been observed. It has been shown, for example, that PCB77, a dioxin-like PCB that activates AHR, caused obesity in mice [71]. A similar finding was observed for dioxin [72]. In contrast, the *P. aeruginosa* pigment molecule, pyocyanin, also an AHR activator, caused inhibition of adipogenesis resulting in wasting syndrome [73]. A recent study identified indigo, a naturally occurring AHR ligand, as having anti-inflammatory properties in visceral adipose tissue that effectively protected against HFD-induced glucose intolerance [74]. In another study it was shown that people and animals with metabolic syndrome had reduced levels of AHR agonist activity in fecal samples [75]. In this case, the deficiency was attributed to the gut microbiota, and supplementation with AHR agonist or a *Lactobacillus* strain with high AHR ligand-production capacity



improved dietary and genetic induced metabolic impairments. Thus, certain AHR agonists may be detrimental in causing metabolic syndrome and others might be protective. Further, some compounds that act as AHR agonists in one context or concentration may act as AHR antagonists in others. Finally, certain AHR agonists and antagonists may act very differently on rodent versus human cells.

In summary, our studies demonstrate a significant role for AHR in obesity and steatosis in male mice on a high-fat diet. The *Pdgfra*-Cre specific knockout of *Ahr* supports a role for AHR that does not directly involve the liver but may be mediated in part through effects on preadipocytes/adipocytes. Further studies, using additional tissue-specific and inducible knockout models, as well as determination of what AHR agonists are produced by high-fat diet will help to define how modulating AHR activities may be useful in prevention and therapeutic interventions for obesity and diabetes.

## Supporting information

**S1 Fig. Cre-mediated recombination of *Ahr* in different tissues and preadipocytes.** A. *Pdgfra*-Cre expression causes recombination to occur between the two loxP sites (black diamonds) surrounding exon 2 of *Ahr* (referred to as floxed), excising the exon and leaving one remaining loxP site. PCR using three primers (P1, P2, and P3) was performed to determine recombination (excision) status. In cells where no recombination occurs (upper structure), P2 and P3 amplify a 140 bp fragment (P1 and P3 are too far apart to achieve any appreciable amplification). In cells where recombination and excision occur (lower structure), the P2 site is removed and P1 and P3 are brought in close proximity to allow amplification of a 180 bp band. B. To verify AHR recombination, the indicated tissues were removed from *Pdgfra*-Cre<sup>pos</sup> *Ahr*<sup>fl/fl</sup> adult mice and processed for DNA. PCR was performed by using published primers [37]. The arrow indicates the upper 180 bp band that demonstrates recombination of the floxed *Ahr* gene (excised) in the tissue. The lower 140 bp band represents non-recombined (unexcised) *Ahr*. The pattern is typical of complex tissue such as adipose tissue where not all the different cell types express *Pdgfra*-Cre. C. Stromal vascular fraction (SVF) consisting mainly of preadipocytes from BAT of 10 neonatal pups derived from the breeding of male *Pdgfra*-Cre<sup>pos/neg</sup> (heterozygous Cre)/*Ahr*<sup>fl/fl</sup> and female *Ahr*<sup>fl/fl</sup> mice that did not express Cre was isolated and cultured for one passage before DNA extraction and assessment for Cre positivity and *Ahr* recombination (excision) by PCR as described in A and in the Materials and Methods. Only the SVF that was Cre positive exhibited a pattern that verified excision. (PDF)

**S2 Fig. Starting weights of 6- to 7-week old male Cre<sup>neg</sup> or *Pdgfra*-Cre<sup>pos</sup> *Ahr*<sup>fl/fl</sup> mice used in the study.** The starting weights of all the mice of the different genotypes, regardless of eventual diet type, were pooled. Statistical analysis was performed using a student t-test in GraphPad Prism. Error bars represent standard error of the mean. (PDF)

**S3 Fig. Daily food intake comparisons between Cre<sup>neg</sup> and *Pdgfra*-Cre<sup>pos</sup> *Ahr*<sup>fl/fl</sup> mice on control or HFD.** Consumption of food of individually housed mice was measured over a week and average daily intake was calculated. Statistical analysis was performed using a One-Way ANOVA with multiple comparisons in GraphPad Prism. Error bars represent standard error of the mean. (PDF)

**S1 Table. Assessment of steatosis in HFD mouse livers.** <sup>a</sup>Ten high-power fields (400X) centered on the terminal hepatic venule (for consistency) were scored for the percentage of the



field with vacuolated cells. <sup>b</sup>Rank was determined by degree of steatosis with a rank of 1 being highest. Ties were designated as equal numbers.

(PDF)

### **S1 Raw images.**

(PDF)

## **Acknowledgments**

The University of Iowa Fraternal Order of Eagles Diabetes Research Center Metabolic Core and the University of Iowa Genomics Core provided advice, resources and equipment for studies presented in this manuscript. We thank Anna Chaly for technical support. We thank Matt Potthoff for advice on animal studies and for making helpful suggestions on the manuscript.

## **Author Contributions**

**Conceptualization:** Francoise A. Gourronc, Kathleen R. Markan, Ryan Sheehy, Dawn E. Quelle, Leonid V. Zingman, Aloysius J. Klingelutz.

**Data curation:** Francoise A. Gourronc, Kathleen R. Markan, Katarina Kulhankova, Zhiyong Zhu, Leonid V. Zingman, Zoya B. Kurago, James A. Ankrum, Aloysius J. Klingelutz.

**Formal analysis:** Francoise A. Gourronc, Kathleen R. Markan, Zoya B. Kurago, James A. Ankrum, Aloysius J. Klingelutz.

**Funding acquisition:** Kathleen R. Markan, Aloysius J. Klingelutz.

**Investigation:** Francoise A. Gourronc, Kathleen R. Markan, Zoya B. Kurago, Aloysius J. Klingelutz.

**Methodology:** Francoise A. Gourronc, Kathleen R. Markan, Leonid V. Zingman, Zoya B. Kurago, James A. Ankrum, Aloysius J. Klingelutz.

**Project administration:** Aloysius J. Klingelutz.

**Supervision:** Aloysius J. Klingelutz.

**Validation:** Aloysius J. Klingelutz.

**Writing – original draft:** Aloysius J. Klingelutz.

**Writing – review & editing:** Francoise A. Gourronc, Kathleen R. Markan, Dawn E. Quelle, Leonid V. Zingman, Zoya B. Kurago, James A. Ankrum, Aloysius J. Klingelutz.

## **References**

1. Huang PL. A comprehensive definition for metabolic syndrome. *Dis Model Mech.* 2009; 2(5–6):231–7. <https://doi.org/10.1242/dmm.001180> PMID: 19407331
2. Nichols GA, Moler EJ. Metabolic syndrome components are associated with future medical costs independent of cardiovascular hospitalization and incident diabetes. *Metab Syndr Relat Disord.* 2011; 9(2):127–33. <https://doi.org/10.1089/met.2010.0105> PMID: 21166586
3. Ogden CL, Carroll MD, Flegal KM. Prevalence of obesity in the United States. *JAMA.* 2014; 312(2):189–90. <https://doi.org/10.1001/jama.2014.6228> PMID: 25005661
4. Cohen P, Spiegelman BM. Cell biology of fat storage. *Mol Biol Cell.* 2016; 27(16):2523–7. <https://doi.org/10.1091/mbc.E15-10-0749> PMID: 27528697
5. Patel P, Abate N. Body fat distribution and insulin resistance. *Nutrients.* 2013; 5(6):2019–27. <https://doi.org/10.3390/nu5062019> PMID: 23739143

6. Patel P, Abate N. Role of subcutaneous adipose tissue in the pathogenesis of insulin resistance. *J Obes.* 2013; 2013:489187. <https://doi.org/10.1155/2013/489187> PMID: 23691287
7. Rosen ED, Spiegelman BM. What we talk about when we talk about fat. *Cell.* 2014; 156(1–2):20–44. <https://doi.org/10.1016/j.cell.2013.12.012> PMID: 24439368
8. Lee MJ, Wu Y, Fried SK. Adipose tissue heterogeneity: implication of depot differences in adipose tissue for obesity complications. *Mol Aspects Med.* 2013; 34(1):1–11. <https://doi.org/10.1016/j.mam.2012.10.001> PMID: 23068073
9. Preis SR, Massaro JM, Robins SJ, Hoffmann U, Vasan RS, Irlbeck T, et al. Abdominal subcutaneous and visceral adipose tissue and insulin resistance in the Framingham heart study. *Obesity (Silver Spring).* 2010; 18(11):2191–8. <https://doi.org/10.1038/oby.2010.59> PMID: 20339361
10. Tchkonja T, Morbeck DE, Von Zglinicki T, Van Deursen J, Lustgarten J, Scoble H, et al. Fat tissue, aging, and cellular senescence. *Aging Cell.* 2010; 9(5):667–84. Epub 2010/08/13. <https://doi.org/10.1111/j.1474-9726.2010.00608.x> PMID: 20701600
11. Rigamonti A, Brennand K, Lau F, Cowan CA. Rapid cellular turnover in adipose tissue. *PLoS One.* 2011; 6(3):e17637. <https://doi.org/10.1371/journal.pone.0017637> PMID: 21407813
12. Cohen P, Spiegelman BM. Brown and Beige Fat: Molecular Parts of a Thermogenic Machine. *Diabetes.* 2015; 64(7):2346–51. <https://doi.org/10.2337/db15-0318> PMID: 26050670
13. Mulero-Navarro S, Fernandez-Salguero PM. New Trends in Aryl Hydrocarbon Receptor Biology. *Front Cell Dev Biol.* 2016; 4:45. <https://doi.org/10.3389/fcell.2016.00045> PMID: 27243009
14. Hubbard TD, Murray IA, Perdew GH. Indole and Tryptophan Metabolism: Endogenous and Dietary Routes to Ah Receptor Activation. *Drug Metab Dispos.* 2015; 43(10):1522–35. <https://doi.org/10.1124/dmd.115.064246> PMID: 26041783
15. Stejskalova L, Dvorak Z, Pavek P. Endogenous and exogenous ligands of aryl hydrocarbon receptor: current state of art. *Curr Drug Metab.* 2011; 12(2):198–212. <https://doi.org/10.2174/138920011795016818> PMID: 21395538
16. Barouki R, Aggerbeck M, Aggerbeck L, Coumoul X. The aryl hydrocarbon receptor system. *Drug Metabol Drug Interact.* 2012; 27(1):3–8. <https://doi.org/10.1515/dmdi-2011-0035> PMID: 22718620
17. Wheeler MA, Rothhammer V, Quintana FJ. Control of immune-mediated pathology via the aryl hydrocarbon receptor. *J Biol Chem.* 2017; 292(30):12383–9. <https://doi.org/10.1074/jbc.R116.767723> PMID: 28615443
18. Stockinger B, Di Meglio P, Gialitakis M, Duarte JH. The aryl hydrocarbon receptor: multitasking in the immune system. *Annu Rev Immunol.* 2014; 32:403–32. <https://doi.org/10.1146/annurev-immunol-032713-120245> PMID: 24655296
19. Murray IA, Patterson AD, Perdew GH. Aryl hydrocarbon receptor ligands in cancer: friend and foe. *Nat Rev Cancer.* 2014; 14(12):801–14. <https://doi.org/10.1038/nrc3846> PMID: 25568920
20. Sorg O. AhR signalling and dioxin toxicity. *Toxicol Lett.* 2014; 230(2):225–33. <https://doi.org/10.1016/j.toxlet.2013.10.039> PMID: 24239782
21. Gustafson B, Hedjazifar S, Gogg S, Hammarstedt A, Smith U. Insulin resistance and impaired adipogenesis. *Trends Endocrinol Metab.* 2015; 26(4):193–200. <https://doi.org/10.1016/j.tem.2015.01.006> PMID: 25703677
22. Alonso-Magdalena P, Quesada I, Nadal A. Endocrine disruptors in the etiology of type 2 diabetes mellitus. *Nat Rev Endocrinol.* 2011; 7(6):346–53. <https://doi.org/10.1038/nrendo.2011.56> PMID: 21467970
23. Kim KS, Lee YM, Kim SG, Lee IK, Lee HJ, Kim JH, et al. Associations of organochlorine pesticides and polychlorinated biphenyls in visceral vs. subcutaneous adipose tissue with type 2 diabetes and insulin resistance. *Chemosphere.* 2014; 94:151–7. <https://doi.org/10.1016/j.chemosphere.2013.09.066> PMID: 24161582
24. Lee DH, Steffes MW, Sjödin A, Jones RS, Needham LL, Jacobs DR Jr. Low dose organochlorine pesticides and polychlorinated biphenyls predict obesity, dyslipidemia, and insulin resistance among people free of diabetes. *PLoS One.* 2011; 6(1):e15977. <https://doi.org/10.1371/journal.pone.0015977> PMID: 21298090
25. Persky V, Piorkowski J, Turyk M, Freels S, Chatterton R Jr., Dimos J, et al. Associations of polychlorinated biphenyl exposure and endogenous hormones with diabetes in post-menopausal women previously employed at a capacitor manufacturing plant. *Environ Res.* 2011; 111(6):817–24. <https://doi.org/10.1016/j.envres.2011.05.012> PMID: 21684538
26. Everett CJ, Frithsen I, Player M. Relationship of polychlorinated biphenyls with type 2 diabetes and hypertension. *J Environ Monit.* 2011; 13(2):241–51. Epub 2010/12/04. <https://doi.org/10.1039/c0em00400f> PMID: 21127808

27. Everett CJ, Thompson OM. Associations of dioxins, furans and dioxin-like PCBs with diabetes and pre-diabetes: is the toxic equivalency approach useful? *Environ Res*. 2012; 118:107–11. <https://doi.org/10.1016/j.envres.2012.06.012> PMID: 22818202
28. Phillips M, Enan E, Liu PC, Matsumura F. Inhibition of 3T3-L1 adipose differentiation by 2,3,7,8-tetrachlorodibenzo-p-dioxin. *J Cell Sci*. 1995; 108 (Pt 1):395–402. PMID: 7537747
29. Alexander DL, Ganem LG, Fernandez-Salguero P, Gonzalez F, Jefcoate CR. Aryl-hydrocarbon receptor is an inhibitory regulator of lipid synthesis and of commitment to adipogenesis. *J Cell Sci*. 1998; 111 (Pt 22):3311–22. PMID: 9788873
30. Cimafranca MA, Hanlon PR, Jefcoate CR. TCDD administration after the pro-adipogenic differentiation stimulus inhibits PPAR $\gamma$  through a MEK-dependent process but less effectively suppresses adipogenesis. *Toxicol Appl Pharmacol*. 2004; 196(1):156–68. <https://doi.org/10.1016/j.taap.2003.12.005> PMID: 15050417
31. Hanlon PR, Cimafranca MA, Liu X, Cho YC, Jefcoate CR. Microarray analysis of early adipogenesis in C3H10T1/2 cells: cooperative inhibitory effects of growth factors and 2,3,7,8-tetrachlorodibenzo-p-dioxin. *Toxicol Appl Pharmacol*. 2005; 207(1):39–58. <https://doi.org/10.1016/j.taap.2004.12.004> PMID: 16054899
32. Kim MJ, Pelloux V, Guyot E, Tordjman J, Bui LC, Chevallier A, et al. Inflammatory pathway genes belong to major targets of persistent organic pollutants in adipose cells. *Environ Health Perspect*. 2012; 120(4):508–14. <https://doi.org/10.1289/ehp.1104282> PMID: 22262711
33. Gadupudi G, Gourronc FA, Ludewig G, Robertson LW, Klingelhutz AJ. PCB126 inhibits adipogenesis of human preadipocytes. *Toxicol In Vitro*. 2015; 29(1):132–41. <https://doi.org/10.1016/j.tiv.2014.09.015> PMID: 25304490
34. Gourronc FA, Robertson LW, Klingelhutz AJ. A delayed proinflammatory response of human preadipocytes to PCB126 is dependent on the aryl hydrocarbon receptor. *Environ Sci Pollut Res Int*. 2018; 25 (17):16481–92. <https://doi.org/10.1007/s11356-017-9676-z> PMID: 28699004
35. Jin UH, Lee SO, Sridharan G, Lee K, Davidson LA, Jayaraman A, et al. Microbiome-derived tryptophan metabolites and their aryl hydrocarbon receptor-dependent agonist and antagonist activities. *Mol Pharmacol*. 2014; 85(5):777–88. <https://doi.org/10.1124/mol.113.091165> PMID: 24563545
36. Huang B, Butler R, Miao Y, Dai Y, Wu W, Su W, et al. Dysregulation of Notch and ER $\alpha$  signaling in AhR $^{-/-}$  male mice. *Proc Natl Acad Sci U S A*. 2016; 113(42):11883–8. <https://doi.org/10.1073/pnas.1613269113> PMID: 27688768
37. Walisser JA, Glover E, Pande K, Liss AL, Bradfield CA. Aryl hydrocarbon receptor-dependent liver development and hepatotoxicity are mediated by different cell types. *Proc Natl Acad Sci U S A*. 2005; 102(49):17858–63. <https://doi.org/10.1073/pnas.0504757102> PMID: 16301529
38. Xu CX, Wang C, Zhang ZM, Jaeger CD, Krager SL, Bottum KM, et al. Aryl hydrocarbon receptor deficiency protects mice from diet-induced adiposity and metabolic disorders through increased energy expenditure. *Int J Obes (Lond)*. 2015; 39(8):1300–9. <https://doi.org/10.1038/ijo.2015.63> PMID: 25907315
39. Wada T, Sunaga H, Miyata K, Shirasaki H, Uchiyama Y, Shimba S. Aryl Hydrocarbon Receptor Plays Protective Roles against High Fat Diet (HFD)-induced Hepatic Steatosis and the Subsequent Lipotoxicity via Direct Transcriptional Regulation of Socs3 Gene Expression. *J Biol Chem*. 2016; 291(13):7004–16. <https://doi.org/10.1074/jbc.M115.693655> PMID: 26865635
40. Wang C, Xu CX, Krager SL, Bottum KM, Liao DF, Tischkau SA. Aryl hydrocarbon receptor deficiency enhances insulin sensitivity and reduces PPAR- $\alpha$  pathway activity in mice. *Environ Health Perspect*. 2011; 119(12):1739–44. <https://doi.org/10.1289/ehp.1103593> PMID: 21849270
41. Moyer BJ, Rojas IY, Kerley-Hamilton JS, Hazlett HF, Nemani KV, Trask HW, et al. Inhibition of the aryl hydrocarbon receptor prevents Western diet-induced obesity. Model for AHR activation by kynurenine via oxidized-LDL, TLR2/4, TGF $\beta$ , and IDO1. *Toxicol Appl Pharmacol*. 2016; 300:13–24. <https://doi.org/10.1016/j.taap.2016.03.011> PMID: 27020609
42. Kerley-Hamilton JS, Trask HW, Ridley CJ, Dufour E, Ringelberg CS, Nurinova N, et al. Obesity is mediated by differential aryl hydrocarbon receptor signaling in mice fed a Western diet. *Environ Health Perspect*. 2012; 120(9):1252–9. <https://doi.org/10.1289/ehp.1205003> PMID: 22609946
43. Baker NA, Shoemaker R, English V, Larian N, Sunkara M, Morris AJ, et al. Effects of Adipocyte Aryl Hydrocarbon Receptor Deficiency on PCB-Induced Disruption of Glucose Homeostasis in Lean and Obese Mice. *Environ Health Perspect*. 2015; 123(10):944–50. <https://doi.org/10.1289/ehp.1408594> PMID: 25734695
44. Jeffery E, Berry R, Church CD, Yu S, Shook BA, Horsley V, et al. Characterization of Cre recombinase models for the study of adipose tissue. *Adipocyte*. 2014; 3(3):206–11. <https://doi.org/10.4161/adip.29674> PMID: 25068087

45. Berry R, Jeffery E, Rodeheffer MS. Weighing in on adipocyte precursors. *Cell Metab*. 2014; 19(1):8–20. <https://doi.org/10.1016/j.cmet.2013.10.003> PMID: 24239569
46. Krueger KC, Costa MJ, Du H, Feldman BJ. Characterization of Cre recombinase activity for in vivo targeting of adipocyte precursor cells. *Stem Cell Reports*. 2014; 3(6):1147–58. Epub 2014/12/03. <https://doi.org/10.1016/j.stemcr.2014.10.009> PMID: 25458893
47. Jeffery E, Church CD, Holtrup B, Colman L, Rodeheffer MS. Rapid depot-specific activation of adipocyte precursor cells at the onset of obesity. *Nat Cell Biol*. 2015; 17(4):376–85. Epub 2015/03/03. <https://doi.org/10.1038/ncb3122> PMID: 25730471
48. Berry R, Rodeheffer MS. Characterization of the adipocyte cellular lineage in vivo. *Nat Cell Biol*. 2013; 15(3):302–8. Epub 2013/02/26. <https://doi.org/10.1038/ncb2696> PMID: 23434825
49. Gao Z, Daquinag AC, Su F, Snyder B, Kolonin MG. PDGFRalpha/PDGFRbeta signaling balance modulates progenitor cell differentiation into white and beige adipocytes. *Development*. 2018; 145(1). Epub 2017/11/22. <https://doi.org/10.1242/dev.155861> PMID: 29158445
50. Wagner G, Lindroos-Christensen J, Einwallner E, Husa J, Zapf TC, Lipp K, et al. HO-1 inhibits preadipocyte proliferation and differentiation at the onset of obesity via ROS dependent activation of Akt2. *Sci Rep*. 2017; 7:40881. Epub 2017/01/20. <https://doi.org/10.1038/srep40881> PMID: 28102348
51. Harrill JA, Hukkanen RR, Lawson M, Martin G, Gilger B, Soldatow V, et al. Knockout of the aryl hydrocarbon receptor results in distinct hepatic and renal phenotypes in rats and mice. *Toxicol Appl Pharmacol*. 2013; 272(2):503–18. <https://doi.org/10.1016/j.taap.2013.06.024> PMID: 23859880
52. Lee JH, Wada T, Febbraio M, He J, Matsubara T, Lee MJ, et al. A novel role for the dioxin receptor in fatty acid metabolism and hepatic steatosis. *Gastroenterology*. 2010; 139(2):653–63. Epub 2010/03/23. <https://doi.org/10.1053/j.gastro.2010.03.033> PMID: 20303349
53. Macotela Y, Boucher J, Tran TT, Kahn CR. Sex and depot differences in adipocyte insulin sensitivity and glucose metabolism. *Diabetes*. 2009; 58(4):803–12. <https://doi.org/10.2337/db08-1054> PMID: 19136652
54. Benede-Ubieto R, Estevez-Vazquez O, Ramadori P, Cubero FJ, Nevzorova YA. Guidelines and Considerations for Metabolic Tolerance Tests in Mice. *Diabetes Metab Syndr Obes*. 2020; 13:439–50. Epub 2020/02/29. <https://doi.org/10.2147/DMSO.S234665> PMID: 32110077
55. Bowe JE, Franklin ZJ, Hauge-Evans AC, King AJ, Persaud SJ, Jones PM. Metabolic phenotyping guidelines: assessing glucose homeostasis in rodent models. *J Endocrinol*. 2014; 222(3):G13–25. Epub 2014/07/25. <https://doi.org/10.1530/JOE-14-0182> PMID: 25056117
56. Markan KR, Naber MC, Ameka MK, Anderegg MD, Mangelsdorf DJ, Kliewer SA, et al. Circulating FGF21 is liver derived and enhances glucose uptake during refeeding and overfeeding. *Diabetes*. 2014; 63(12):4057–63. <https://doi.org/10.2337/db14-0595> PMID: 25008183
57. Galarraga M, Campion J, Munoz-Barrutia A, Boque N, Moreno H, Martinez JA, et al. Adiposoft: automated software for the analysis of white adipose tissue cellularity in histological sections. *J Lipid Res*. 2012; 53(12):2791–6. <https://doi.org/10.1194/jlr.D023788> PMID: 22993232
58. Klingelutz AJ, Gourronc FA, Chaly A, Wadkins DA, Burand AJ, Markan KR, et al. Scaffold-free generation of uniform adipose spheroids for metabolism research and drug discovery. *Sci Rep*. 2018; 8(1):523. <https://doi.org/10.1038/s41598-017-19024-z> PMID: 29323267
59. Kang J, Gu Y, Li P, Johnson BL, Sucov HM, Thomas PS. PDGF-A as an epicardial mitogen during heart development. *Dev Dyn*. 2008; 237(3):692–701. <https://doi.org/10.1002/dvdy.21469> PMID: 18297729
60. Sheka AC, Adeyi O, Thompson J, Hameed B, Crawford PA, Ikramuddin S. Nonalcoholic Steatohepatitis: A Review. *JAMA*. 2020; 323(12):1175–83. Epub 2020/03/25. <https://doi.org/10.1001/jama.2020.2298> PMID: 32207804
61. Kajimura S, Spiegelman BM, Seale P. Brown and Beige Fat: Physiological Roles beyond Heat Generation. *Cell Metab*. 2015; 22(4):546–59. <https://doi.org/10.1016/j.cmet.2015.09.007> PMID: 26445512
62. Eske K, Newsome B, Han SG, Murphy M, Bhattacharyya D, Hennig B. PCB 77 dechlorination products modulate pro-inflammatory events in vascular endothelial cells. *Environ Sci Pollut Res Int*. 2014; 21(10):6354–64. <https://doi.org/10.1007/s11356-013-1591-3> PMID: 23504249
63. Han SG, Han SS, Toborek M, Hennig B. EGCG protects endothelial cells against PCB 126-induced inflammation through inhibition of AhR and induction of Nrf2-regulated genes. *Toxicol Appl Pharmacol*. 2012; 261(2):181–8. <https://doi.org/10.1016/j.taap.2012.03.024> PMID: 22521609
64. Lahoti TS, John K, Hughes JM, Kusnadi A, Murray IA, Krishnegowda G, et al. Aryl hydrocarbon receptor antagonism mitigates cytokine-mediated inflammatory signalling in primary human fibroblast-like synoviocytes. *Ann Rheum Dis*. 2013; 72(10):1708–16. <https://doi.org/10.1136/annrheumdis-2012-202639> PMID: 23349129

65. Gourronc FA, Perdew GH, Robertson LW, Klingelutz AJ. PCB126 blocks the thermogenic beiging response of adipocytes. *Environ Sci Pollut Res Int.* 2020; 27(9):8897–904. Epub 2019/11/14. <https://doi.org/10.1007/s11356-019-06663-0> PMID: 31721030
66. Moyer BJ, Rojas IY, Kerley-Hamilton JS, Nemani KV, Trask HW, Ringelberg CS, et al. Obesity and fatty liver are prevented by inhibition of the aryl hydrocarbon receptor in both female and male mice. *Nutr Res.* 2017; 44:38–50. <https://doi.org/10.1016/j.nutres.2017.06.002> PMID: 28821316
67. Jaeger C, Xu C, Sun M, Krager S, Tischkau SA. Aryl hydrocarbon receptor-deficient mice are protected from high fat diet-induced changes in metabolic rhythms. *Chronobiol Int.* 2017; 34(3):318–36. <https://doi.org/10.1080/07420528.2016.1256298> PMID: 28102700
68. Liu JJ, Movassat J, Portha B. Emerging role for kynurenines in metabolic pathologies. *Curr Opin Clin Nutr Metab Care.* 2019; 22(1):82–90. Epub 2018/11/09. <https://doi.org/10.1097/MCO.0000000000000529> PMID: 30407222
69. Jaeger C, Tischkau SA. Role of Aryl Hydrocarbon Receptor in Circadian Clock Disruption and Metabolic Dysfunction. *Environ Health Insights.* 2016; 10:133–41. <https://doi.org/10.4137/EHI.S38343> PMID: 27559298
70. Jaeger C, Khazaal AQ, Xu C, Sun M, Krager SL, Tischkau SA. Aryl Hydrocarbon Receptor Deficiency Alters Circadian and Metabolic Rhythmicity. *J Biol Rhythms.* 2017; 32(2):109–20. <https://doi.org/10.1177/0748730417696786> PMID: 28347186
71. Arsenescu V, Arsenescu RI, King V, Swanson H, Cassis LA. Polychlorinated biphenyl-77 induces adipocyte differentiation and proinflammatory adipokines and promotes obesity and atherosclerosis. *Environ Health Perspect.* 2008; 116(6):761–8. Epub 2008/06/19. <https://doi.org/10.1289/ehp.10554> PMID: 18560532
72. Brulport A, Le Corre L, Chagnon MC. Chronic exposure of 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) induces an obesogenic effect in C57BL/6J mice fed a high fat diet. *Toxicology.* 2017; 390:43–52. <https://doi.org/10.1016/j.tox.2017.07.017> PMID: 28774668
73. Larian N, Ensor M, Thatcher SE, English V, Morris AJ, Stromberg A, et al. Pseudomonas aeruginosa-derived pyocyanin reduces adipocyte differentiation, body weight, and fat mass as mechanisms contributing to septic cachexia. *Food Chem Toxicol.* 2019; 130:219–30. <https://doi.org/10.1016/j.fct.2019.05.012> PMID: 31078726
74. Lin YH, Luck H, Khan S, Schneeberger PHH, Tsai S, Clemente-Casares X, et al. Aryl hydrocarbon receptor agonist indigo protects against obesity-related insulin resistance through modulation of intestinal and metabolic tissue immunity. *Int J Obes (Lond).* 2019; 43(12):2407–21. <https://doi.org/10.1038/s41366-019-0340-1> PMID: 30944419
75. Natividad JM, Agus A, Planchais J, Lamas B, Jarry AC, Martin R, et al. Impaired Aryl Hydrocarbon Receptor Ligand Production by the Gut Microbiota Is a Key Factor in Metabolic Syndrome. *Cell Metab.* 2018; 28(5):737–49 e4. <https://doi.org/10.1016/j.cmet.2018.07.001> PMID: 30057068